Targeting severe symptoms of early 2023-new outbreak of COVID-19 by classical drug dexamethasone: a potential fatality reducing agent
| dc.contributor.author | Dongsheng Liu | |
| dc.contributor.author | Aamir Saeed | |
| dc.contributor.author | Sidra Majaz | |
| dc.contributor.author | Bashrat Ahmad | |
| dc.contributor.author | Ashfaq Ahmad | |
| dc.contributor.author | Yingqiu Xie | |
| dc.date.accessioned | 2025-08-22T12:14:13Z | |
| dc.date.available | 2025-08-22T12:14:13Z | |
| dc.date.issued | 2023-05-26 | |
| dc.description.abstract | binding analysis for five strains (Omicron, BJ. | en |
| dc.identifier.citation | Liu Dongsheng, Saeed Aamir, Majaz Sidra, Ahmad Bashrat, Ahmad Ashfaq, Xie Yingqiu. (2023). Targeting severe symptoms of early 2023-new outbreak of COVID-19 by classical drug dexamethasone: a potential fatality reducing agent. Journal of Translational Medicine. https://doi.org/10.1186/s12967-023-04186-4 | en |
| dc.identifier.doi | 10.1186/s12967-023-04186-4 | |
| dc.identifier.uri | https://doi.org/10.1186/s12967-023-04186-4 | |
| dc.identifier.uri | https://nur.nu.edu.kz/handle/123456789/10002 | |
| dc.language.iso | en | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | Journal of Translational Medicine | en |
| dc.rights | All rights reserved | en |
| dc.source | Journal of Translational Medicine, (2023) | en |
| dc.subject | Outbreak | en |
| dc.subject | Case fatality rate | en |
| dc.subject | Dexamethasone | en |
| dc.subject | Coronavirus disease 2019 (COVID-19) | en |
| dc.subject | Drug | en |
| dc.subject | Medicine | en |
| dc.subject | Virology | en |
| dc.subject | Pandemic | en |
| dc.subject | 2019-20 coronavirus outbreak | en |
| dc.subject | Environmental health | en |
| dc.subject | Intensive care medicine | en |
| dc.subject | Pharmacology | en |
| dc.subject | Internal medicine | en |
| dc.subject | Infectious disease (medical specialty) | en |
| dc.subject | Disease | en |
| dc.subject | Population | en |
| dc.subject | type of access: open access | en |
| dc.title | Targeting severe symptoms of early 2023-new outbreak of COVID-19 by classical drug dexamethasone: a potential fatality reducing agent | en |
| dc.type | letter | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Targeting_severe_symptoms_of_early_2023-new_outbreak_of_COVID-19_by_classical_drug_dexamethasone__a_potential_fatality_r__584b5ac6.pdf
- Size:
- 1.82 MB
- Format:
- Adobe Portable Document Format